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Cumulative evidence has shown that a delicate balance between serine proteases and their inhibitors is
crucial for normal functioning of several biological pathways. The importance of proteases and their
inhibitors is well documented in several human diseases. Among them, the best documented are hemophilia
B, a genetic deﬁciency of the serine protease coagulation factor IX and serpinophathies. Alpha-1-antitrypsin
deﬁciency (MIM 107400), is associated with early-onset emphysema and liver disease, while hereditary
angioedema (HANE; MIM 106100) is caused by mutations in the C1 inhibitor, a serpin involved in the
regulation of the complement cascade. Recently, two human genetic diseases of the central nervous system
have been related to mutations in components of extracellular proteolytic systems. Here, we review the
recent advances in this ﬁeld.
INTRODUCTION
Serine proteases is a group of enzymes that catalyzes hydrolysis
of peptide bonds via a nucleophilic attack triggered by their
active site serine. Serine proteases act sequence-specifically and
are usually synthesized and secreted as inactive proenzymes
(called zymogens) further activated by proteolysis. The best
characterized members of this family play a role in intestinal
digestion, blood coagulation and fibrinolysis (i.e. trypsin,
thrombin or plasmin). In addition, several studies have
pointed out the role of serine proteases in the central nervous
system (CNS) (1). Indeed, during neural development, serine
proteases contribute to cell migration, axon outgrowth and
synapse elimination. In adult, they play a role in neuropeptide
processing, regulation of neuronal survival and structural
plasticity associated with learning and memory processes.
Their mechanism of action probably involves degradation
of extracellular matrix components, activation/inhibition of
protease activated receptors (PARs) or activation/inhibition of
other serine proteases. For instance, urokinase-plasminogen
activator (uPA) and tissue type-plasminogen activator (tPA)
convert plasminogen into active plasmin which in turn remodels
synaptic connections via the degradation of an extracellular
matrix component, laminin (2). In addition, tPA has been repor-
ted to cleave N-methyl-D-aspartate (NMDA) receptors and,
thereby, regulate the function of glutamatergic synapses (3).
Similarly, thrombin induces a proteolytic activation of PAR-1,
resulting in the activation of protein kinase C, which reduces the
voltage-dependent Mg2þ blockade of NMDA channels. Finally,
neuropsin, a serine protease exclusively expressed in the central
nervous system, cleaves the Ig superfamily cell adhesion
molecule L1, which is located in the presynaptic membrane
and plays an important role in the maintenance of long-term
potentiation (LTP) (4).
A DELICATE PROTEASE/ANTIPROTEASE
BALANCE
Extracellular proteolysis by serine proteases often involves
regulatory antiproteases called serpins (5–7). The serine
protease inhibitors of the serpin family act by binding to the
active site of their target protease(s) (8). This physiological
inhibitory mechanism involves docking of the serpin to the
target protease, cleavage of the reactive center loop, and rapid
translocation of the protease to the opposite pole of the serpin
(8). Protease nexin-1 (PN-1), the first identified neural serpin, is
expressed in glia and neurons (9–11). It is a potent inhibitor of
thrombin, but it can also inhibit tPA. Mice overexpressing
PN-1 in neurons show increased LTP in the CA1 field of
hippocampal slices and develop progressive disturbances
of motor behavior and sensorimotor integration, while
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PN-1-deficient mice have decreased hippocampal LTP (12,13).
Both overexpression and lack of PN-1 cause epileptic activity
in vivo and in vitro.
Neuroserpin, the second neural serpin, has been recognized
as an axonally secreted member of the serpin superfamily (14).
Searches for target proteases (15,16) revealed strong inhibition
of tPA and uPA and to a somewhat lesser degree of plasmin, but
no action against thrombin was noted. The half-life of
neuroserpin/tPA complexes may be shorter than usually found
in cognate protease–serpin pairs (17). This raises the question
of whether tPA is really the cognate target protease of
neuroserpin. Plasminogen activator inhibitor 1 (PAI-1), the
cognate inhibitor of tPA in plasma, is not normally expressed in
the brain, although it may be induced after exitotoxic injury
(18). Therefore, it is possible that the cognate target of
neuroserpin may be another, as yet unidentified, serine
protease. Likewise, the activity of tPA activity in the brain
might be controlled by an inhibitor other than neuroserpin.
NEUROTRYPSIN MUTATION IN AUTOSOMAL
RECESSIVE MENTAL RETARDATION
Mental retardation (MR) is a frequent disorder affecting about 3%
of the population (19). The severity of mental retardation is
commonly classified on the basis of intelligence quotient (IQ)
although other criteria have also been used. Assuming a
population mean of 100 and a standard deviation of 15, MR is
usually classified as ‘mild’ when the IQ ranges between 50 and 70
and as ‘severe’ when the IQ value is below 50 (20). The causes of
MR are diverse and include environmental factors, teratogens,
chromosomal anomalies and metabolic diseases impairing
neuronal function. Genetically determined forms of severe MR
average largely 25–50% (21,22). MRs of genetic origin include
metabolic diseases impairing neuronal function in a non-specific
manner and conditions which alter the normal patterning of the
brain. However, the most common form of MR is not linked to
metabolic disorders or abnormal brain development, nor any other
clinical features and, therefore, is termed non-syndromic MR. An
autosomal recessive mode of inheritance may account for nearly a
quarter of mentally retarded individuals with non-syndromic MR.
However, while 11 genes for non-syndromic X-linked MR have
been found, none of the genes causing non-syndromic autosomal
recessive MR had been identified until recently.
We analyzed a large consanguineous Algerian family, in
which four out of eight children (three girls and one boy) were
affected by a severe impairment of cognitive functions with an
IQ below 50 (23). Because the parents were first-degree
cousins, we suspected an autosomal-recessive pattern of
inheritance. By means of a genome-wide screen with 400
microsatellite markers, we identified a single region of shared
homozygosity on chromosome 4q24–q25 in the four affected
individuals. A detailed sequence analysis of selected genes of
this region revealed a 4 bp deletion in the neurotrypsin gene.
Neurotrypsin is a neuronal serine protease predominantly
expressed in neurons of the cerebral cortex, the hippocampus
and the amygdala (24). By immuno-electronmicroscopy,
neurotrypsin was localized in the presynaptic membrane and
the presynaptic active zone of both asymmetrical (excitatory)
and symmetrical (inhibitory) synapses (Fig. 1). In vitro studies
have demonstrated that it is a secreted protein which remains
associated with the presynaptic membrane after its secretion.
Neurotrypsin shows a unique domain composition (25).
It consists of a proline-rich basic segment, one kringle domain,
four scavenger receptor cysteine-rich (SRCR) domains, and a
protease domain (Fig. 2). The 4 bp deletion, located in the 7th
exon, is most likely a null allele as it is predicted to result in a
shortened protein lacking the catalytic domain (Fig. 2). These
findings, therefore, indicate neurotrypsin as the first gene to
be identified as a cause of a nonsyndromic autosomal recessive
form of MR.
A neurotrypsin defect does not appear to be a common cause
of MR. We did not find any evidence for neurotrypsin
mutations in individuals affected with MR in 17 non-
syndromic inbread families. However, we found the same
4 bp deletion in another child born to first-cousin Algerian
parents. The two families appear unrelated, but originate from
the same area of Eastern Algeria. In both families, the mutation
was carried on the background of the same haplotype across
the neurotrypsin locus, suggesting a founder effect in the
Algerian population.
The pathophysiological phenotype and the age of onset of the
disease in affected individuals is consistent with the function of
neurotrypsin as a regulator of adaptive synaptic functions, such
as synapse reorganization during later stages of neurodevelop-
ment and adult synaptic plasticity. In all affected children
the course of the disease was similar. They reached the
milestones of normal psychomotor development in the first 18
months. Signs of mental retardation were first observed by their
parents when they were around 2 years of age. This suggests
that neurotrypsin function is crucial in later stages of brain
development. Normal cerebral MRI indicates the absence of
gross neurodevelopmental abnormalities and a normal ratio
between gray and white matter. This suggests that neurotrypsin
Figure 1. Immuno-electronmicroscopic localization of neurotrypsin in the pre-
synaptic active zone of a CNS synapse. (A) Schematic drawing of a CNS
synapse. The presynaptic terminal contains numerous synaptic vesicles (green)
containing neurotransmitter. Mitochondria deliver energy required for the
various presynaptic processes, such as transmitter synthesis and transport, the
exocytosis of synaptic vesicles, and their recycling by endocytosis.The triangles
(yellow) indicate the presynaptic active zones, i.e. the sites where synaptic
vesicles dock and release their content by fusion of their membrane with
the presynaptic plasma membrane lining the synaptic cleft. (B) Electron-
microscopic image of a CNS synapse showing the localization of neurotrypsin
in the presynaptic membrane and the presynaptic active zone. Neurotrypsin was
visualized by an affinity-purified antibody against the proteolytic domain,
followed by a secondary antibody conjugated with peroxidase, in order to
generate an electron-dense precipitate at the location of the antigen.
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does not play a critical role in formation of synapses, but rather
may be crucial for adaptive synaptic functions, such as
those required to establish and/or maintain higher cognitive
functions. Taken together, these results provide the first
evidence for an association between cognitive impairment
and defects in extracellular proteolytic activity at the synapse,
opening a novel field in the pathophysiology of mental
retardation. The recent generation of mice deficient in the
catalytic domain of neurotrypsin in CNS neurons and of
mice over-expressing neurotrypsin will provide further insight
into the function of this protein.
MUTATIONS OF NEUROSERPIN IN FAMILIAL
ENCEPHALOPATHY WITH NEUROSERPIN
INCLUSION BODIES (FENIB)
Familial encephalopathy with neuroserpin inclusion bodies
(FENIB, MIM 604218) is an autosomal dominant disorder
causing dementia and epilepsy (26). This novel familial disease
has first been reported in two Caucasian families living in the
USA. In the larger family, affected individuals presented
clinically around the fifth decade of life with cognitive decline,
including deficits in attention and concentration, difficulties in
response regulation, and impaired visuospatial skills. Memory
was also impaired, but to a lesser degree than is typically seen
in patients with Alzheimer disease. After several years of
disease progression, most affected individuals were unable to
work and eventually required nursing-home care. The second
family showed an earlier clinical onset, during the second or
third decade of life. Affected individuals presented with both
epilepsy and progressive cognitive decline that eventually
required hospitalization. Cognitive changes in mildly to
moderately affected subjects were characteristic for deficits in
processes dependent on frontal areas. The main neuropatholo-
gical finding in the two families was the presence of eosino-
philic neuronal inclusions distributed throughout the deeper
layers of the cerebral cortex and in many subcortical nuclei,
especially in the substantia nigra. These inclusions, called
Collins bodies, are round, 5–50 mm in diameter, and strongly
positive for periodic acid Schiff (PAS) but diastase resistant.
Biochemical analysis of the inclusion bodies purified from a
postmortem brain revealed neuroserpin as the single major
protein. Molecular analysis of the neuroserpin gene allowed
Davis and colleagues to identify a single point mutation
in each family (a ser49-to-pro and a ser52-to-arg mutation,
respectively) (26). Three other families with neuroser-
pin mutations have been described since. In one of these
families with two affected family members, the same ser52-to-
arg mutation was found, although the two families were
unrelated. The two other families bear different neuroserpin
mutations (gly392-to-glu and his338-to-arg, respectively) (27).
Interestingly, all disease-causing mutations known so far are
clustered in the so-called shutter region (Fig. 3). The shutter
region is a small area found in all inhibitory serpin species that
controls the shutter-like opening and closure of the superficial
four-stranded b-sheet, into which a segment of the reactive site
loop is inserted during the inhibitory interaction of the serpin
with its target serine protease (8).
Neuroserpin is a serine protease inhibitor of the serpin family
that has been identified as an axonally secreted glycoprotein in
neuronal cultures of chicken dorsal root ganglia (28). In vivo, it
is first expressed during late stages of neurogenesis and it has
been postulated that neuroserpin plays a role during later stages
of synaptogenesis. Persistence of neuroserpin expression
during adulthood also suggests a role in adult synaptic
plasticity. In vitro studies with cultured hippocampal neurons
demonstrated that transcription of neuroserpin mRNA is
regulated by electrical activity and increased by depolarization
with elevated extracellular KCl. Neuroserpin may act as an
activity-regulated modulator of proteolytic activity supporting
the hypothesis that proteolytic processes at CNS synapses are
involved in mechanisms regulating or realizing structural
changes associated with synaptic plasticity (29). In addition,
mice overexpressing neuroserpin in CNS neurons under the
control of the Thy-1 promoter and mice deficient in neuro-
serpin have been generated (30). Both deviations from normal
neuronal neuroserpin expression result in a marked disturbance
of the explorative behavior and severe neophobia (30).
The mutated forms of neuroserpin resulting in FENIB deviate
from wild-type neuroserpin both in enzymological and
physicochemical characteristics. All four mutations found in
FENIB are thought to induce neuroserpin polymerization by
loop–sheet interaction followed by precipitation. For the ser49-
to-pro mutation, a pronounced reduction of the proteinase
inhibitor function compared to wild-type neuroserpin has been
determined (31). Although for mutated neuroserpin no
functional studies are available at the cellular and the systemic
level, it is generally accepted that intracellular precipitation
and formation of Collins bodies (formed by intracellular
precipitation of neuroserpin) underlies the clinical manifestation.
Figure 2. Domain composition of wild-type neurotrypsin and the truncated
form of neurotrypsin generated by the 4 bp deletion in exon 7. (A) Wild-type
neurotrypsin is composed of a proline-rich basic segment at the aminoterminus
(PB), a Kringle domain (KR), four scavenger receptor cysteine-rich domains
(SRCR1-4), and a serine protease domain (PROT). Molecular modeling
revealed a specificity pocket wide and deep enough to accommodate a basic
amino acid (arginine or lysine). The PB domain may mediate cell surface or
ECM attachment. (B) Truncated neurotrypsin generated by the 4 bp deletion
in exon 7. The frameshift caused by the 4 bp deletion results in a nonsense
sequence leading to a shortened ill-folded third SRCR domain. The fourth
SRCR and the protease domain are missing due to the premature termination
of translation.
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This is best supported by the strong link between the extent of
the conformational changes associated with the tendency to
precipitate and the onset and the severity of dementia (27).
Based on molecular modeling, a functional role of these
mutations for the stability of the molecule was predicted. The
extent of the conformational changes with regards to the
propensity of the mutated protein to aggregate that were
predicted for the four mutations showed a clear correlation with
the age of onset and the severity of dementia in the affected
individuals of the five families.
The progressive myoclonus epilepsy that dominates the
clinical picture during the early stages of the more severe forms
of FENIB is thought to be due to a preferential degeneration
of inhibitory neurons. As highest expression of neuroserpin
is found in GABA-ergic neurons (C. Cen, V. Meskanaite, and
P. Sonderegger, unpublished data), degeneration due to
intracellular neuroserpin precipitation could affect inhibitory
neurons prior to excitatory neurons, resulting in a disrupted
balance between excitatory and inhibitory activites in the
affected regions. A dysfunction of inhibitory neurons could
alternatively be explained by a reduced proteinase inhibitory
function of mutated neuroserpin (31). However, recently
generated mice deficient in neuroserpin exhibit a pronounced
difference in their exploratory behavior and an abnormal
reaction to novel objects, but no seizures or any other signs of
altered excitability (30). In summary, FENIB shows a clear
genotype-phenotype correlation with the severity of the disease
correlating with the propensity of the mutated neuroserpin
to form polymers, demonstrating that intracellular protein
aggregation is responsible for neurodegeneration (27).
MANY OTHER SUSPECTS . . .
Further pieces of evidence suggesting that the balance between
serine proteases and their inhibitors should be further examined
in relation to diseases of the CNS come from analyses of
animal models. tPA-deficient mice perform poorly in two-way
avoidance tests and exhibit a perturbance in long-lasting LTP
(32). By contrast, transgenic mice with neuronal overexpres-
sion of tPA exhibit enhanced LTP (33). Both overexpression
and inactivation of neural protease nexin-1, a serine protease
inhibitor of the serpin family, altered hippocampal LTP (12).
Finally, abnormalities of both neurons and synapses have been
observed in neuropsin-deficient mice (34). Interestingly,
neuropsin is able to cleave the cell adhesion molecule L1
(L1CAM) at the synapse (4), while molecular defects in the
L1CAM gene are responsible for X-linked hydrocephalus
associated with MR (35). These genes are therefore good
candidates for being involved in other mental retardation
syndromes.
Figure 3. Localization of the precipitation-causing mutations of neuroserpin in the ‘shutter region’. The spatial structure of neuroserpin is shown as a ribbon diagram
based on its crystal structure (38). The inhibitory interaction between a serpin and a target protease induces a shutter-like opening between strands 3 and 5 of the
superficial b-sheet that allows part of the reactive site loop (RSL, blue) to be inserted as the fourth strand. The b-strands of the superficial b-sheet are presented
in green and numbered 2, 3, 5 and 6 in the magnified window. The inserted RSL is drawn in blue and numbered as strand 4. Strands 3 and 4 are made partially trans-
parent in order to allow sight on the underlying structures. The accommodation of the RSL requires a sliding movement of the b-strands of the superficial b-sheet on
the underlying peptide scaffold. All four disease-causing mutations (colored in pink) affect amino acids located in the ‘shutter region’ and are thought to perturb the
function of the shutter. This in turn results in the insertion of the reactive site loop of one neuroserpin molecule into the superficial b-sheet of another, whose reactive
site loop inserts into the superficial b-sheet of a next neuroserpin molecule, etc, resulting in polymerization and precipitation of mutated neuroserpin.
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Another interesting point is that alterations of the human
Reelin gene is associated with an autosomal recessive form of
lissencephaly (36). Lissencephaly is a severe developmental
disorder in which neuronal migration is impaired, leading to a
thickened cerebral cortex whose normally folded contour is
simplified and smooth. The Reelin protein is essential for
correct cytoarchitectonic organization during CNS develop-
ment. Mutations of the Reelin gene in mouse disrupts neuronal
migration in several brain regions and gives rise to functional
deficits, such as ataxic gait and trembling. Thus, reelin is
thought to control cell–cell interactions critical for cell
positioning in the brain. Its function in adult brain is far less
well understood, but altered brain and blood reelin levels have
been reported in some psychiatric disorders. An involvement of
the reelin signaling pathway in neurodegeneration has been
suggested. Recently, it was reported that reelin has proteolytic
activity. By in vitro studies, the capacity of reelin to degrade the
adhesion molecules fibronectin and laminin was convincingly
demonstrated (37). The effect of reelin on neuronal migration
may therefore be mediated by its ability to modulate cell
adhesion through its proteolytic activity.
CONCLUSION
Impaired proteolysis appears to be associated with a broad
range of defects and the increasing number of studies
describing the effects of serine proteases on glial and neuronal
function suggests that these proteins may be involved in many
others diseases of the nervous system. The association of
neurotrypsin defect with isolated mental retardation is
of particular interest, as it confirms that synaptic proteolysis
plays a key role in cognitive function. Unraveling the molecular
bases of other forms of neurological diseases not associated
with mutations in neurotrypsin or neuroserpin will possibly
involve other components of the extracellular proteolysis
signaling pathway. The careful description of these phenotypes,
combined with the study of disease causing mutations in
animal models will help elucidate the targets of these proteins.
Hopefully, identifying these targets will in turn contribute to
a better management of these conditions.
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